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Abstract 
Background: The oncogenic role of the fibroblast growth factor receptor (FGFR) has been recognized in a number of 
different cancer types. However, the prognostic significance of FGFRs has not been elucidated yet in cervical cancer. 
In the present study, we investigate the expression of FGFRs and their prognostic value in cervical cancer patients.
Methods: FGFR1, FGFR2, FGFR3, and FGFR4 expression was determined by immunohistochemistry in conjunc‑
tion with quantitative digital image analysis of 336 formalin‑fixed, paraffin‑embedded cervical cancer tissues and 61 
normal cervical tissues, as well as NCI60 cell microarray. Subsequently, the association between clinicopathological 
characteristics and patient survival was assessed.
Results: FGFRs proteins were differentially expressed in the NCI60 cell line panel and showed considerable correla‑
tion between protein and mRNA expression. The expression of FGFR1, FGFR2, and FGFR4 were higher in cancer tissues 
than in normal tissues, whereas the expression of FGFR3 was higher in normal tissues. FGFR1 was highly expressed in 
adeno‑/adenosquamous carcinoma (P = 0.020), while FGFR2, FGFR3, and FGFR4 expression were more prominent in 
squamous cell carcinoma (P < 0.001, P < 0.001, and P = 0.020, respectively). FGFR2 expression was significantly higher 
in small sized tumors (P = 0.020). Additionally, high FGFR2 and FGFR4 were correlated with negative lymph node 
metastasis (P = 0.048 and P = 0.040, respectively). FGFR1, FGFR2, and FGFR3 were highly expressed in tumors without 
parametrial involvement (P = 0.030, P = 0.005, and P = 0.010, respectively). In survival analysis, high expressions of 
FGFR2, FGFR3, and FGFR4 was associated with longer disease‑free survival (P = 0.006, P = 0.035, P = 0.001, respec‑
tively) and overall survival (P = 0.003, P = 0.002, P = 0.003, respectively). Notably, the co‑expression of all three FGFRs 
was significantly associated with favorable disease‑free survival (P < 0.001) and overall survival (P < 0.001), compared 
to the negative expressions of the three FGFRs. The prognostic significance persisted in the cox regression analysis.
Conclusions: The frequent expression of members of the FGFR family in cervical cancer suggests they may have 
prognostic and therapeutic relevance.
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Background
Cervical cancer is the third most common type of can-
cer among women worldwide, and is the most prevalent 
female malignancy in many developing countries [1, 2]. 
Although preventive vaccination and screening are good 
in prevention, invasive cancer continues to occur, even 
among women who have access to cancer screening, 
and the prognosis remains poor in patients with a bulky 
tumor or adenocarcinoma histology [3–5]. Clinical fac-
tors such as International Federation of Gynecology and 
Obstetrics (FIGO) stage, lymph node metastasis, and 
tumor size may serve as prognostic markers, however 
they are insufficient in accurately predicting recurrence 
and survival. Thus, biomarkers, including molecular 
markers, are needed. Patient care would be considerably 
improved if tumor behavior could be reliably prognosti-
cated at the time of initial diagnosis.
The mammalian fibroblast growth factor (FGF) fam-
ily comprises 18 ligands that exert their actions through 
four transmembrane tyrosine kinase receptors; fibroblast 
growth factor receptor (FGFR) 1, FGFR2, FGFR3, and 
FGFR4. The FGF/FGFR system is responsible for multiple 
cellular functions, including proliferation, differentiation, 
survival, and motility [6–9]. Considering these func-
tions, it is no surprise they are susceptible to aberration 
in cancer cells [10]. Several types of genetic alterations 
have been recognized in cancers, including gene ampli-
fications, activating mutations, chromosomal translo-
cations, and aberrant splicing at the posttranscriptional 
level [10]. For instance, FGFR1 mutations and amplifica-
tions have been implicated in prostate [11], breast [12] 
and lung cancers [13], whereas aberrant FGFR2 expres-
sion has been observed in endometrial [14], breast [15], 
and gastric cancer [16]. Furthermore, activating muta-
tions and overexpression of FGFR3 have been reported 
in bladder cancers [17] and multiple myeloma [18]. We 
have identified mutation in FGFR4, which acts as an 
oncogene, and suggested therapeutic targeting of FGFR4 
in rhabdomyosarcomas [19]. In addition, we recently 
examined a prevalent occupational exposure suscepti-
bility variants associated with increased bladder cancer 
risk, and observed an additive interaction for rs798766 
(TMEM129-TACC3-FGFR3) with the interaction more 
apparent in patients with tumors positive for FGFR3 
expression [20]. In cervical cancer, recent studies have 
shown the possible involvement of aberrant FGFR signal-
ing with human papillomavirus (HPV) 16 E5 expression 
[21]. Notably, FGFR2 expression has been reported to be 
associated with cell growth and progression of cervical 
dysplasia [22, 23].
Recently, alterations in the FGFR signaling pathway 
have gained the spotlight due to their high incidence 
rate and therapeutic potential in malignancies [24]. 
Nevertheless, protein expression of the FGFR system and 
its prognostic significance in cervical cancer has not yet 
been elucidated. Thus, the aim of this study is to inves-
tigate the clinical significance of FGFR1, FGFR2, FGFR3 
and FGFR4 expression in a well-defined cohort of cervi-
cal cancers, using immunohistochemistry and quantita-
tive digital image analysis.
Methods
Patients and tumor samples
In the present study, we retrieved a total of 336 early stage 
cervical cancer patients treated in the Department of 
Gynecologic Oncology, Samsung Medical Center, Sung-
kyunkwan University School of Medicine between 2002 
and 2009. Patients with rare histology such as sarcoma, 
malignant melanoma, and neuroendocrine carcinoma, 
and patients with limited availability of tissue block spec-
imens were excluded from the tissue microarray (TMA) 
construction. 61 non-matched, non-adjacent normal epi-
thelial tissues were used for the control. Tissue samples 
were collected from patients who had signed an informed 
consent form, which was approved by the Institutional 
Review Board at the Samsung Medical Center, Seoul, 
Korea (2009-09-002-002 and 2015-07-122). Some of the 
paraffin blocks were provided by the Korea Gynecologic 
Cancer Bank through Bio & Medical Technology Devel-
opment Program of the Ministry of Education, Science 
and Technology, Korea (NRF-2012M3A9B8021800). This 
study was additionally approved by the Office of Human 
Subjects Research at the National Institute of Health.
All patients were treated primarily with radical hyster-
ectomy with or without pelvic/para-aortic lymph node 
dissection. Patients received adjuvant radiotherapy with 
or without concurrent chemotherapy if they had risk 
factors. Following treatment, patients had follow-up 
examinations every 3 months for the first 2 years, every 
6  months for the next 3  years, and once annually every 
year thereafter. Disease-free survival (DFS) was assessed 
from the date of surgery to the date of recurrence or the 
date of the last follow-up visit. Overall survival (OS) was 
measured from the date of surgery to the time of death, 
or for the living patients, to the date of last contact.
Tissue microarray construction and immunohistochemistry
Tissue microarrays (TMAs) were constructed from tissue 
blocks used for routine pathological evaluation. In each 
case, areas with the most representative histology were 
selected, and cylindrical tissue samples (0.6  mm) were 
cored from the donor block and extruded into the recipi-
ent array. We included three cores from separate tissue 
blocks of each patient to reduce sampling bias.
NCI60 cell microarray was constructed as previously 
described [25]. In brief, NCI60 cells were collected and 
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then fixed in 70 % ethanol. After fixation, cells were pel-
leted and added 3 % low-melt agarose (SeaPlaque, Cam-
brex, Rockland, ME). The cells were immediately evenly 
dispersed in the warm by vortexing, and placed on ice 
for 2 min to form agar plugs. The agarose plug was trans-
ferred into a histology cassette (Tissue-TekTM, Sakura 
Finetek, Torrance, CA) and then processed in Tissue-
Tek VIP processor (Sakura) and subsequently paraffin-
embedded to form a donor block. Finally, the NCI60 cell 
microarray was constructed using 1.0 mm needle.
Immunohistochemical staining of FGFR1, FGFR2, 
FGFR3 and FGFR4 was performed on 4-μm sections of 
the TMA and NCI60 cell microarray, as described previ-
ously [26]. In brief, following deparaffinization and dehy-
dration, heat-induced antigen retrieval was performed for 
20 min in an antigen retrieval buffer of pH 9.0 (for FGFR3 
and FGFR4) or pH 6.0 (for FGFR1 and FGFR2) (Dako, 
Carpinteria, CA) using a steam pressure cooker (Pascal, 
Dako). The endogenous peroxidase activity was blocked 
with 3 % H2O2 for 10 min. For FGFR1 and FGFR2, sec-
tions were incubated with protein block (Dako) for fur-
ther 15  min. The sections were subsequently incubated 
with primary antibodies, a detailed list of which, along 
with dilutions, is provided in Additional file 1: Table S1. 
The antigen–antibody reaction was detected with Dako 
EnVision+Dual Link System-HRP (Dako) and DAB+ (3, 
3′-Diaminobenzidine; Dako). In the negative control sec-
tions, the primary antibody was omitted. Positive con-
trols included umbilical cord, stomach carcinoma, skin 
tissue, and prostate cancer for FGFR1, FGFR2, FGFR3, 
and FGFR4 antibodies, respectively. Tissue sections were 
lightly counterstained with hematoxylin and examined by 
light microscopy.
Quantitative evaluation of immunostaining
The evaluation of immunostaining was carried out using 
computer-assisted image analyzing software version 
4.5.1.324 (Visiopharm, Hoersholm, Denmark,). Immu-
nohistochemically stained slides were scanned using a 
NanoZoomer 2.0 HT (Hamamatsu Photonics, Hama-
matsu City, Japan) at 20× objective magnification (0.5-
μm resolution), and captured digital images were then 
imported into the Visiopharm software. Each core was 
imported separately using the TMA workflow of the 
program.
Digital images consist of pixels, each of which is defined 
by a position and a value of intensity [27]. After training 
the system by digitally “painting” examples of the nucleus 
in the image, tumor nuclei were defined (Additional file 2: 
Figure S1A–B). Cytoplasm is further defined by outlining 
the defined nucleus (Additional file  2: Figure S1C). The 
mean intensity of DAB for each defined image is used for 
quantification of the expressions (Additional file 2: Figure 
S1D). The intensity of staining was categorized as 0, 1+, 
2+, and 3+ according to the distribution pattern across 
cores. The final score was calculated by multiplying the 
intensity and percentage of staining resulting in a final 
histoscore of 0–300 [28].
Microarray gene expression profiling
To examine the prognostic significance of mRNA 
expression, microarray data were analyzed as described 
previously [29]. In brief, RNA was extracted from for-
malin-fixed, paraffin-embedded tissue sections with 
removal of nontumor elements. RNA was extracted 
using the High Pure RNA Paraffin kit (Roche Diagnos-
tic, Mannheim, Germany) and subsequently, the whole 
genome cDNA mediated annealing selection and liga-
tion (WG-DASL) assay was performed following the 
manufacturer’s instructions (Illumina, San Diego, CA). 
With the exclusion of inadequate samples, a total of 300 
patient samples were evaluable and the expression data 
was deposited in the Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc= GSE44001).
In‑silico analysis for TCGA cervix
To evaluate the prognostic significance of FGFR mRNA 
expression, data from The Cancer Genome Atlas (TCGA) 
Research Network were also analyzed (http://cancerge-
nome.nih.gov/). Pan-cancer normalized form of RNA-
seq data of cervical cancers, which had been obtained 
using a Illumina HiSeq (Illumina, San Diego, CA, USA), 
were downloaded (version: 2015-02-24). For survival 
analysis, the mRNA expression value was dichotomized 
according to quartile values (lower than 25 percentile vs. 
higher than 75 percentile).
Statistical analysis
Statistical analysis was performed using the R soft-
ware version 3.1.2. The expression level of the proteins 
according to the clinicopathological characteristics were 
analyzed using a Student’s t test. Analysis of the Spear-
man rho coefficient was used to assess associations and 
correlations between parameters. For survival analysis, 
expression values were dichotomized (positive vs. nega-
tive) with the cut-off values showing the most discrimi-
native power in the univariate cox model for disease-free 
survival (Additional file  2: Figure S1E) (R package: sur-
vMisc). Survival distributions were estimated using the 
Kaplan–Meier method, and the relationship between 
survival and each parameter was analyzed with the log-
rank test. A Cox proportional hazards model was created 
to identify independent predictors of survival. Statisti-
cal significance was considered to be present at values of 
P < 0.05.
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Results
Clinicopathological characteristics of patients
Clinicopathological characteristics of 336 patients are 
summarized in Table  1. Patients with IB2 or IIB who 
were treated primarily with radical surgery were included 
in the present study. One hundred and sixty patients 
(47.6  %) were treated with adjuvant radiation, with or 
without concurrent chemotherapy following radical 
surgery.
FGFRs expression in the NCI60 cell lines
The NCI60 cell lines are widely used cancer biology and 
drug discovery. In addition, the NCI60 cell microarray is 
a useful platform for antibody validation because immu-
nohistochemistry (IHC) data of NCI60 cell microarray 
are used to predict antibody titer for IHC on multi-tumor 
TMA [25]. Thus, we performed IHC on NCI60 cell 
microarray to assist in assessment of antibody specificity.
A total of 58 cell lines were analyzed by hierarchical 
clustering with the continuous histoscore. As shown in 
Fig. 1, three categories were defined. Category 1 (n = 29) 
consists relatively of low FGFR1, FGFR2, and FGFR4 
expression. In contrast, category 3 (n  =  20) consists 
exclusively of high FGFR1, FGFR2, and FGFR4 expres-
sion. Furthermore, category 2 (n  =  9) consists exclu-
sively of low FGFR3 expression. FGFR2 and FGFR4 
protein expression was correlated with mRNA expression 
(r = 0.308; P = 0.019 and r = 0.413; P = 0.004, respec-
tively) (Fig.  1b). Although FGFR1 and FGFR3 did not 
meet statistical significance there is a positive correlation 
trend. These data suggest that FGFRs proteins were dif-
ferentially expressed in the NCI60 cell lines and antibod-
ies of FGFR isoforms had specificity.
FGFR expression and its associations 
with clinicopathological features
FGFR1, FGFR2, FGFR3 and FGFR4 expression is mainly 
observed in the cytoplasm [30–32], and representative 
examples of positive and negative staining are shown 
in Fig.  2. Determination of the cut-offs for expression 
of FGFRs was also referenced to overall survival. The P 
value of the predicted log-rank test of Kaplan–Meier 
results was plotted against the normalized staining values 
(Additional file 2: Figure S2) and supports the determina-
tion of cut-offs for FGFR2, FGFR3, and FGFR4 based on 
the histogram. FGFR1 expression lacked as clear a rela-
tionship between expression and outcome by this analy-
sis. Among the 336 tumors investigated, the number of 
tumors exhibiting high FGFR expression was 88 (26.2 %, 
histoscore >122) for FGFR1, 167 (49.7 %, histoscore >58) 
for FGFR2, 211 (62.8  %, histoscore >57) for FGFR3 and 
241 (71.7 %, histoscore >79) for FGFR4. When compared 
with normal tissues, the expression of FGFR1, FGFR2, 
and FGFR4 were higher and the expression of FGFR3 
was lower in cancer tissues (Table 2). The expression of 
FGFR was cell type associated. FGFR1 was more highly 
expressed in adeno-/adenosquamous carcinoma, while 
FGFR2, FGFR3, and FGFR4 expression was more promi-
nent in squamous cell carcinoma (P = 0.020, P < 0.001, 
P  <  0.001, and P =  0.020, respectively) (Table  2). These 
results suggest that each FGFR potentially has a different 
role according to cell type in cervical cancers.
Table 1 Clinicopathological characteristics of  the 336 cer-
vical cancer patients
FIGO International Federation of Gynecology and Obstetrics; SCC squamous 
cell carcinoma; Ag antigen; AD adenocarcinoma; ASC adenosquamous 
cell carcinoma; LVSI lymphovascular space invasion; LN lymph node; 
PM parametrium; OP operation; RT radiotherapy; CCRT concurrent 
chemoradiotherapy
Frequency %
Age
 Mean ± SD 48.9 ± 11.2
FIGO stage
 IB1/IIA 291 86.6
 IB2/IIB 45 13.4
Cell type
 SCC 256 76.2
 AD/ASC 80 23.8
Tumor size
 ≤4 cm 256 76.2
 >4 cm 80 23.8
SCC Ag level (ng/ml)
 Median (range) 1.2 (0.1–65.1)
LVSI
 Negative 202 60.1
 Positive 134 39.9
Depth of invasion
 <50 % 108 32.1
 >50 % 228 67.9
LN metastasis
 Negative 256 76.2
 Positive 80 23.8
PM involvement
 Negative 305 90.8
 Positive 31 9.2
Resection margin
 Negative 323 96.1
 Positive 13 3.9
Primary treatment
 OP only 171 50.9
 OP + RT 70 20.8
 OP + CCRT 90 26.8
 Neoadjuvant 5 1.5
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In addition, the high expression of FGFR1, FGFR2, 
FGFR3 were negatively correlated with the parame-
trial involvement (P = 0.030, P = 0.005, and P = 0.010, 
respectively). Furthermore, FGFR2 expression was 
down-regulated in large-sized (P  =  0.020) and lymph 
node metastatic (P =  0.048) tumors. FGFR4 expression 
was also down-regulated in lymphovascular space inva-
sive (P = 0.004) and lymph node metastatic (P = 0.040) 
tumors. These results indicate that FGFR expression is 
associated with less aggressive phenotypes in cervical 
cancers.
In order to find the clustering of samples according 
to FGFR expression, a total of 336 cervical cancer cases 
were analyzed by hierarchical clustering with the contin-
uous histoscore. As shown in Additional file 2: Figure S3, 
two categories were defined. Category 1 (n = 116) con-
sists exclusively of high FGFR2 and FGFR3 expression. 
In contrast, category 2 (n =  220) consists exclusively of 
low FGFR1, FGFR2, and FGFR3 expression. Furthermore, 
there are significant differences for cell type, tumor size, 
lymph node metastasis and primary treatment between 
category 1 and category 2 (Additional file  1: Table S2). 
Notably, category 2 associated with advanced tumor 
phenotypes and had poor prognosis. Subsequently, we 
examined the correlation among FGFR1-4 expression. 
FGFR1 expression was positively correlated with FGFR2, 
FGFR3, or FGFR4 expression (r =  0.445, r =  0.366 and 
r  =  0.373, respectively; all P  <  0.001). Furthermore, 
FGFR2 expression was positively correlated with FGFR3, 
or FGFR4 expression (r = 0.576, and r = 0.413, respec-
tively; all P < 0.001). There was also a significant correla-
tion between FGFR3 and FGFR4 expression (R = 0.381, 
P < 0.001) (Fig. 3).
High expression of FGFR2, FGFR3, and FGFR4 predict 
longer survival
With a median follow-up period of 66  months (range 
1–143), five-year disease-free survival and overall 
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Fig. 1 FGFRs expression in the NCI60 cell lines. a Hierarchical clustering analysis for immunohistochemical expression of FGFR1, FGFR2, FGFR3, and 
FGFR4. Three categories were defined. Category 1 (n = 29) consists relatively of low FGFR1, FGFR2, and FGFR4 expression. In contrast, category 3 
(n = 20) consists exclusively of high FGFR1, FGFR2, and FGFR4 expression. Category 2 (n = 9) consists exclusively of low FGFR3 expression. b Cor‑
relation between FGFRs mRNA and protein expression. mRNA expression level was measured by microarray gene expression profiling, whereas the 
protein expression was assessed by immunohistochemistry. FGFR2 and FGFR4 protein expression was correlated with mRNA expression (P = 0.019 
and P = 0.004, respectively)
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survival rates for the whole group were 87  % (95  % CI 
83–91) and 96  % (95  % CI 93–98), respectively. A 
high expression of FGFR2, FGFR3, and FGFR4 was 
significantly associated with favorable disease-free sur-
vival (P = 0.006, P = 0.035, and P = 0.001, respectively) 
and overall survival (P = 0.003, P = 0.002, and P = 0.003, 
a b
c d
e f
g h
Fig. 2 FGFR1, FGFR2, FGFR3, and FGFR4 expression in formalin‑fixed, paraffin‑embedded cervical cancer tissues. Representative immunohisto‑
chemical images of FGFR1 negative (a) and positive (b), FGFR2 negative (c) and positive (d), FGFR3 negative (e) and positive (f), FGFR4 negative (g) 
and positive (h) expression. The Scale bar represents 50 μm
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respectively) (Additional file  2: Figures S3A, S4A). The 
5  year disease-free survival was 92, 90, and 91  % for 
patients with a high expression of FGFR2, FGFR3, and 
FGFR4, respectively, compared with 81, 82, and 76 % for 
patients with a low expression. Similarly, the 5 year over-
all survival was 99, 97, and 97 % for patients with positive 
Table 2 Correlation between FGFR expression and clinicopathological characteristics of cervical cancer
FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; Ag antigen; AD adenocarcinoma; ASC adenosquamous cell carcinoma; LVSI 
lymphovascular space invasion; LN lymph node; PM parametrium; OP operation; RT radiotherapy; CCRT concurrent chemoradiotherapy
FGFR1 FGFR2 FGFR3 FGFR4
Mean histoscore [95 % CI] Mean histoscore [95 % CI] Mean histoscore [95 % CI] Mean histoscore [95 % CI]
Normal vs. cancer
 Normal 35 [27–42] 32 [23–40] 106 [89–124] 68 [57–80]
 Cancer 84 [77–91] 70 [64–77] 82 [76–87] 129 [122–136]
 P value <0.001 <0.001 0.02 <0.001
Stage
 IB1/IIA 82 [75–90] 72 [64–79] 83 [76–89] 130 [121–138]
 IB2/IIB 89 [70–107] 66 [48–83] 79 [65–93] 117 [97–136]
 P value 0.520 0.520 0.630 0.220
Cell type
 SCC 78 [71–86] 77 [69–85] 89 [82–96] 133 [124–141]
 AD/ASC 99 [83–115] 51 [40–62] 59 [48–71] 113 [98–128]
 P value 0.020 <0.001 <0.001 0.020
Tumor size
 ≤4 cm 85 [77–93] 74 [667–83] 83 [76–90] 131 [122–139]
 >4 cm 79 [64–91] 59 [47–70] 79 [68–89] 120 [105–134]
 P value 0.330 0.020 0.500 0.210
LVSI
 Negative 84 [75–93] 73 [64–82] 84 [76–93] 137 [127–147]
 Positive 82 [71–93] 67 [57–77] 78 [70–87] 114 [104–126]
 P value 0.770 0.390 0.330 0.004
Depth of invasion
 <50 % 88 [75–101] 73 [60–86] 85 [74–97] 132 [118–146]
 >50 % 81 [73–90] 70 [62–78] 80 [73–87] 126 [117–135]
 P value 0.420 0.670 0.490 0.470
LN metastasis
 Negative 83 [75–91] 74 [66–82] 84 [77–91] 132 [124–141]
 Positive 84 [70–98] 60 [48–72] 75 [65–83] 114 [98–129]
 P value 0.920 0.048 0.160 0.040
PM involvement
 Negative 85 [78–93] 73 [66–80] 83 [77–90] 129 [121–137]
 Positive 65 [48–82] 49 [34–64] 64 [50–78] 115 [91–139]
 P value 0.030 0.005 0.010 0.250
Resection margin
 Negative 83 [76–90] 71 [64–78] 82 [76–88] 128 [121–136]
 Positive 88 [50–127] 70 [42–99] 80 [52–108] 118 [75–161]
 P value 0.780 0.970 0.890 0.620
Primary treatment
 OP only 84 [74–94] 81 [70–91] 91 [81–100] 136 [125–147]
 OP + RT 81 [66–96] 67 [53–81] 73 [62–85] 127 [111–143]
 OP + CCRT 83 [70–96] 54 [45–64] 71 [62–81] 115 [100–129]
 Neoadjuvant 86 [2–171] 96 [17–175] 96 [20–173] 119 [38–199]
 P value 0.990 0.051 0.120 0.180
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FGFR2, FGFR3, and FGFR4 expression respectively, com-
pared with 93, 93, and 91 % for patients with a negative 
expression (Fig. 4). Furthermore, patients with a combi-
nation of high expression of FGFR2 and FGFR3, FGFR2 
and FGFR4, or FGFR3 and FGFR4 had significantly more 
favorable disease-free survival (P  =  0.004, P  <  0.001, 
P < 0.001, respectively) and overall survival (all P < 0.001) 
(Fig.  4; Additional file  2: Figures S3B, S4B). Addition-
ally, the coexpression of all three FGFRs was significantly 
associated with favorable disease-free survival and over-
all survival (both P  <  0.001) compared with the single 
expression of FGFR.
Using the Cox proportional hazards model, the expres-
sions of FGFR2 and FGFR4 remained an independ-
ent prognostic factor for disease-free survival [hazard 
ratio  =  0.51 (95  % CI 0.27–0.97), P  =  0.040; hazard 
ratio = 0.51 (95 % CI 0.28–0.91), P = 0.020, respectively) 
(Table  3). With respect to overall survival, the expres-
sions of FGFR2, FGFR3, and FGFR4 remained an inde-
pendent factor [hazard ratio = 0.24 (95 % CI 0.07–0.83), 
P  =  0.020; hazard ratio  =  0.29 (95  % CI 0.11–0.78), 
P  =  0.010; hazard ratio  =  0.33 (95  % CI 0.13–0.83), 
P  =  0.020, respectively). All the combination mark-
ers with FGFR2, FGFR3, and FGFR4 showed independ-
ent factors for disease-free survival and overall survival 
(Additional file 1: Table S3; Table 3). Notably, the prog-
nostic value of FGFR expression was not influenced by 
cell type.
Based on the clinical significance of FGFRs protein 
expressions, the clinical implications of FGFR1, FGFR2, 
FGFR3, and FGFR4 mRNA expressional levels were 
assessed. Notably, there was a similar finding between 
transcription and translation expression levels in cervical 
cancer. FGFR2 had a significantly favorable prognostic 
significance at the mRNA level from the GSE44001 data-
set (Additional file 2: Figure S5). The RNA-seq dataset of 
TCGA cervix also showed a favorable prognostic signifi-
cance of FGFR2 and FGFR3 (Additional file 2: Figure S6).
Discussion
In the present study, we investigated the prognostic sig-
nificance of FGFR1, FGFR2, FGFR3, and FGFR4 expres-
sion in a large cohort of cervical cancer patients. Here, 
we identified that the FGFRs were differentially expressed 
according to cell types of cervical cancer. Furthermore, 
we demonstrate for the first time that elevated expression 
of FGFR2, FGFR3, or FGFR4 predict favorable survival in 
cervical cancer patients. These results suggest that FGFR 
protein analysis can be a prerequisite in the diagnostic 
procedure of cervical cancer, and may guide the patients’ 
Fig. 3 Relationship among FGFR1, FGFR2, FGFR3, and FGFR4 expression in cervical cancer tissues. There is a significant positive correlation between 
each FGFR expression (P < 0.001)
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therapy. In addition, quantitative digital image analy-
sis used in this study shows potential for more objective 
results with possible better prognostication. We tested 
methods of combining the FGFRs expression to predict 
outcome, as has been demonstrated in the combination 
of different targets within pathways [33, 34], however 
were unable to demonstrate a relationship of co-expres-
sion that is predictive of outcome.
Published prognostic significances of FGFRs are con-
troversial as there are studies reporting higher recurrence 
rates with positive FGFR expression, and others finding 
significantly lower recurrence rates in FGFR express-
ing tumors [7, 10, 17, 35–37]. FGFR2 has been found to 
be highly expressed in colorectal cancer and correlated 
with tumor growth, invasion, and angiogenesis, and 
stronger FGFR2 expression has been observed in the 
invasive front of colorectal cancer cells [35]. In addition, 
there was positive correlation between advanced tumor 
stage and a high expression of FGFR2 in rectal cancers 
[36]. On the obverse, down-regulation of FGFR2 in blad-
der cancers was associated with an adverse prognosis [7]. 
And, in FGFR2 amplified breast cancer cell lines, consti-
tutive signaling appeared to confer a survival advantage 
over non amplified cell lines [38]. FGFR3 have also been 
discussed as a potential prognostic markers in several 
Fig. 4 Kaplan–Meier survival curves for overall survival according to FGFR1, FGFR2, FGFR3, and FGFR4. a Cervical cancer patients with high FGFR2, 
FGFR3, and FGFR4 expression had longer overall survival (P = 0.003, P = 0.002, and P = 0.003, respectively) than those with low expression. b The 
combination of FGFR2, FGFR3, and FGFR4 was found to enhance prognostic accuracy for cervical cancer. The patients with FGFR2+/FGFR3+/
FGFR4+ expression had significantly longer overall survival (P < 0.001) than those with FGFR2‑/FGFR3‑/FGFR4‑ expression. P values were obtained 
from log‑rank tests
Table 3 Multivariate analysis of  the association 
between prognostic variables and survival in cervical can-
cer patients
DFS disease-free survival; HR hazard ratio; OS overall survival; CI confidence 
interval; FIGO International Federation of Gynecology and Obstetrics; 
AD adenocarcinoma; SCC squamous cell carcinoma; LN lymph node; PM 
parametrium
Variables Disease‑free survival Overall survival
DFS HR [95 % CI],  
P value
OS HR [95 % CI],  
P value
FIGO stage  
(IB2/IIB vs. IB1/IIA)
1.72 [0.86–3.47], 0.090 2.00 [0.70–5.73], 0.190
Cell type  
(AD vs. SCC)
3.80 [2.10–6.86], <0.001 5.89 [2.37–14.65], <0.001
LN metastasis 4.15 [2.20–7.83], <0.001 2.89 [1.12–7.49], 0.030
Tumor size (>4 cm) 0.96 [0.49–1.88], 0.910 0.90 [0.32–2.54], 0.840
PM involvement 1.31 [0.58–2.94], 0.520 1.72 [0.52–5.69], 0.380
FGFR1+ 0.52 [0.25–1.11], 0.090 0.48 [0.16–1.50], 0.210
FGFR2+ 0.51 [0.27–0.97], 0.040 0.24 [0.07–0.83], 0.020
FGFR3+ 0.56 [0.30–1.03], 0.060 0.29 [0.11–0.78], 0.010
FGFR4+ 0.51 [0.28–0.91], 0.020 0.33 [0.13–0.83], 0.020
FGFR2+/FGFR3+ 0.37 [0.17–0.82], 0.010 0.13 [0.03–0.60], 0.010
FGFR2+/FGFR4+ 0.30 [0.13–0.68], 0.004 0.17 [0.05–0.63], 0.008
FGFR3+/FGFR4+ 0.33 [0.15–0.69], 0.004 0.11 [0.03–0.44], 0.002
FGFR2+/FGFR3+/
FGFR4+
0.24 [1.10–0.60], 0.002 0.08 [0.02–0.40], 0.002
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cancers, however data remain controversial [39–41]. 
Mutations of the FGFR3 gene are one of the most fre-
quent genetic alterations in bladder cancer and have been 
shown to be associated with tumors with a favorable 
prognosis [42–44]. With respect to protein expression, 
correlation of FGFR3 overexpression with low-grade and 
low-stage bladder cancers has been reported [6, 7, 37]. 
Conversely, there are studies reporting an association 
between the overexpression of the FGFR3 protein and 
poor survival in breast cancer [45]. There are few stud-
ies examining the prognostic significance of FGFR4. In 
breast cancer, wild type FGFR4 has been proposed to 
be an important tumor suppressor via the regulation of 
genes controlling invasion like matrix metalloproteinase 
1, suggesting loss of wild type FGFR4 would adversely 
influence disease progression [46]. Our previous report 
showed over expression of FGFR4 in rhabdomyosarcoma, 
and furthermore, activating mutation of FGFR4 can pro-
mote metastasis in human rhabdomyosarcomas [19].
These contradictory results may be attributed in part to 
the cell type specificity. For instance, IIIb and IIIc isoforms 
of FGFR1 and FGFR2 are expressed in epithelial and mes-
enchymal cells, respectively [47]. In addition, the cell type 
specificity can change when FGFRs are associated with 
cancer. Secondly, the prognostic significance can be differ-
ent according to mechanism and nature of what is meas-
ured. Significance of protein expression can differ from 
other aberration such as mutation, amplification, or trans-
locations frequently seen in the FGFR pathway. Our pre-
sent results support the idea that FGFR protein expression 
is a strong indicator concerning prognosis and survival.
HPV is a well-known etiologic agent in cervical can-
cer, and persistent infection leads to a genomic insta-
bility and local immune suppression, which can lead to 
both the accumulation of genomic alterations in the host 
cell, as well as to the integration of the viral genome into 
the host genome [48]. Recently, genome-wide studies 
have described the genomic and epigenomic alterations 
of HPV-associated cancers, which highlighted multiple 
potential biomarkers and therapeutic targets [49–53]. In 
addition to recurrent integrations in RAD51B, NR4A2, 
and TP63, additional genomic alterations were found in 
receptor tyrosine kinases, primarily FGFR2 and FGFR3, 
in HPV-positive head and neck squamous cell carcinoma 
[49]. FGFR2 and FGFR3 mutations have been identified 
among 17.6 % of HPV-positive tumors, and both muta-
tions have been described in several cancer types, and are 
sensitive to FGFR inhibitors [54, 55]. Although there is 
the heterogeneity of HPV-related tumors at different ana-
tomical sites, alteration of FGFR2 and FGFR3 could also 
be worthwhile to study in cervical cancers.
In the present study, we used quantitative digital 
image analysis for immunohistochemistry scoring. The 
advantage of this analysis is, once the analysis protocol 
has been defined for a given application, large volumes of 
image data can be processed with minimal user-interac-
tion allowing a highly standardized output on a continu-
ous scale. The prognostic significance of FGFR expression 
seen in this study, support the usefulness of the image 
analysis. As quantitative digital image analysis becomes 
more established, the acknowledgement of results on a 
continuous scale is likely to become widely accepted and 
beneficial for improved data mining.
Conclusions
In conclusion, the present study investigated the immu-
nohistochemical expression of FGFR1, FGFR2, FGFR3, 
and FGFR4 in a large number of cervical cancer patients. 
FGFR2, FGFR3, and FGFR4 expression were elevated 
in squamous cell carcinoma, and a high expression of 
FGFR1, FGFR2, FGFR3, and FGFR4 were associated 
with a less aggressive phenotype. Furthermore, a high 
expression of FGFR2, FGFR3, and FGFR4 showed longer 
disease-free survival and overall survival. Cox regres-
sion analysis confirmed that FGFR2, FGFR3, and FGFR4 
expression was an important prognostic indicator in cer-
vical cancer. This information could have clinical value in 
identifying cervical cancer patients who are at low risk of 
progression.
Additional files
Additional file 1. Table S1. Antibodies used for immunohistochemistry. 
Table S2. Association between clinicopathological characteristics and 
two groups defined by cluster analysis. Table S3. Univariate analysis of 
the association between prognostic variables and survival in cervical 
cancer patients.
Additional file 2. Figure S1. Digital image analysis of the nucleus and 
cytoplasm staining. With the original image (A), nucleus (B) and cytoplasm 
(C) are classified, and the mean intensity for each fields are presented in a 
histogram format (D) which enables grouping of the cells by intensity (0, 
1+, 2+, and 3+). The final histoscore was calculated by multiplying the 
intensity and percentage of staining resulting in a range of 0 to 300. Test 
statistics indicate the discriminative power in the univariate cox model 
for disease‑free survival (R package: survMisc) (E). Nuclear and cytoplas‑
mic area highlighted in green and red, respectively. Dashed vertical lines 
indicate the chosen cut‑off values (FGFR1 = 122, FGFR2 = 58, FGFR3 = 
57, and FRGR4 = 79). Figure S2. Plots to find the best cut‑off values. The 
p‑value of the predicted log‑rank test of Kaplan‑Meier results was plotted 
against the normalized staining values. Figure S3. Hierarchical clustering 
analysis for immunohistochemical expression of FGFR1, FGFR2, FGFR3, 
and FGFR4. (A) Two groups (Category 1 and 2) are defined. Category 1 
(n = 116) consists exclusively of high FGFR2 and FGFR3 expression. In 
contrast, category 2 (n = 220) consists exclusively of low FGFR1, FGFR2, 
and FGFR3 expression. (B) The patients with Category 1 had significantly 
longer overall survival (P = 0.024) than those with Category 2. P‑values 
were obtained from log‑rank tests. Figure S4. Kaplan‑Meier survival 
curves for disease free survival according to FGFR1, FGFR2, FGFR3, and 
FGFR4. (A) Cervical cancer patients with high FGFR2, FGFR3, and FGFR4 
expression had longer disease‑free survival (P = 0.006, P = 0.035, and P 
= 0.001, respectively) than those with low expression. (B) The combina‑
tion of FGFR2, FGFR3, and FGFR4 was found to enhance prognostic 
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